Opens in a new tab or window The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo ...

For the multifaceted and complex diseases, multi-omics could define groups of patients with distinct endotypes exhibiting heterogeneous treatment responses due to their particular underlying molecular ...

Activating agents enable the efficient preparation of organozinc complexes from zinc metal and organohalides, but their mechanisms had been obscured by the heterogeneous nature of these systems.

New research identifies key cellular mechanism driving Alzheimer's disease. ScienceDaily . Retrieved January 20, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241223135051.htm ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs for Polymyositis does not have sufficient historical data ...